March 05, 2021
Per-patient-per-year (PPPY) costs for diffuse large B-cell lymphoma (DLBCL) in the United States are considerable, with many patients requiring treatment beyond their first line of therapy, according to a real-world study published online ahead of print in The Oncologist.
“Most incident and prevalent patients were treated with ≥1 lines of therapy, and a substantial portion of these patients required additional lines of therapy,” researchers wrote. “Among patients treated with ≥1 lines of therapy, total PPPY health care costs were $137,156 in incident patients and $81,669 in prevalent patients; more than 60% of these costs were driven by outpatient visits.”
The retrospective analysis included data for 1877 patients with incident DLBCL and 651 patients with prevalent DLBCL (identified through a prior diagnosis code for unspecified DLBCL or primary mediastinal large B-cell lymphoma).
The most common first-line therapy was R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), which was administered to 65.3% of patients with incident DLBCL and 66.8% of patients with prevalent DLBCL, according to the study. After their first line of therapy, 22.6% of patients with incident DLBCL and 38.4% of patients with prevalent DLBCL required additional therapy.
Patients with incident DLBCL had 1.3 inpatient visits and 42 outpatient visits PPPY, researchers reported. Patients with prevalent DLBCL had 0.8 inpatient visits and 31.3 outpatient visits PPPY.
At $88,202 PPPY, outpatient costs were the main driver of total costs, according to the study. Outpatient costs were higher the first year after diagnosis, a sensitivity analysis showed.
“This real-world assessment of patient characteristics, treatment patterns, health care resource use, and costs highlights the substantial clinical and economic burden of patients diagnosed with DLBCL and treated with an identifiable 1L therapy,” researchers wrote. “Furthermore, this study shows that a large portion of patients require additional therapy after 1L treatment to manage DLBCL, highlighting the significant unmet need in this population.”
Yang X, Laliberté F, Germain G, et al. Real-World Characteristics, Treatment Patterns, Healthcare Resource Use and Costs of Patients with Diffuse Large B-Cell Lymphoma in the United States [published online ahead of print, 2021 Feb 22]. Oncologist. 2021;10.1002/onco.13721. doi:10.1002/onco.13721